Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Regulatory News

PDA's Regulatory News is a source of pertinent news from all over the globe. This section is set up by distinct parts of the world so you can read what is crucial to you and your company.

  • ORA, CDER Align on Manufacturing

    Nov 3, 2017

    The U.S. FDA continues to restructure its field activities, moving away from a geographic focus to a structure based on program-aligned commodity areas. As part of this process, CDER and the Office of Regulatory Affairs (ORA) recently began implementing a concept of operations agreement that better aligns drug review programs with facility inspections. Both field and review staff will work together as part of a team-based approach that provides a holistic overview of all elements that create risk, from drug substance to drug product to manufacturing.

    The Agency hopes this alignment will help prevent manufacturing delays due to inspection issues.

    Read more
  • FDA Looks at PACs for Biologics

    Sep 15, 2017

    In early August, the U.S. FDA released the draft guidance, CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports. This draft guidance provides recommendations to holders of biologics license applications for specified products regarding the types of minor changes that need to be documented in an annual report. In particular, the document outlines CMC controls for post-approval changes the Agency considers to have minimal adverse impact on product. Under current regulations, such minor changes must be documented in an annual report.

    Comments are due Oct. 10.

    Read more
  • Supply Chain Pilot Commenting Period Extended

    Jul 5, 2017

    The U.S. FDA has extended the commenting period relating to supply chain elements of the Drug Supply Chain Security Act (DSCSA). The Agency is requesting comments on product identifiers for product tracing, supply chain technical capabilities, and identification of system attributes needed under the DSCSA.

    Comments now close April 30, 2018.

    Read more
  • FDA, EMA Agree on Mutual Reliance

    Mar 10, 2017

    In early March, both the US FDA and EMA announced that the European Union and United States have agreed to recognize each region’s GMP inspections of pharmaceutical manufacturing facilities. This agreement follows three years of work between both agencies on the Mutual Reliance Initiative. Mutual recognition of inspections is expected to result in avoidance of duplicate inspections, reduced inspection costs, and allows regulators to better allocate resources to other regions that present greater risks.

    The European Union is expected to have completed its assessment of FDA by Nov. 1, with FDA having completed its own assessment of eight EU member states.

    Read more
  • FDA Establishes Oncology CoE

    Mar 10, 2017

    The US FDA has established the Oncology Center of Excellence (OCE) and appointed Richard Pazdur, MD, as its director. The OCE is part of the FDA’s larger effort to better address the needs of cancer patients through a coordinated clinical review of drugs, biologics, and devices across the Agency’s three medical product centers.

    Read more
  • FDA Making Strides with MRI

    Jan 27, 2017

    The FDA recently announced that the Agency hopes to sign an agreement with the European Union soon on the Mutual Reliance Initiative (MRI). At this time, the two entities are completing assessments of drug manufacturing inspectorates for two to four EU countries. The Agency launched this initiative with the EU in 2014 to create an expanded inspectorate that enables FDA investigators and trusted EU partners to work together to avoid duplicate inspections by relying on each region’s inspection information. This would allow the United States and European Union to devote more resources to regions where drug manufacturing has greatly increased, such as China and India.

    Read more
  • New System for U.S. Drug Imports

    Jan 27, 2017

    Effective Dec. 29, certain data on FDAregulated products imported into the United States must be submitted through the Agency’s Automated Commercial Environment (ACE) system. This more streamlined import process is expected to result in efficient use of Agency resources and more effective enforcement of FDA regulations. ACE replaces the older Automated Commercial System. The new system offers a single window for importers, eliminating the need to submit information more than once.

    Read more
  • Owners Responsible for Quality

    Jan 27, 2017

    The FDA released a guidance for industry on Nov. 22 describing how contract manufacturing organizations can use quality agreements to delineate their manufacturing activities to ensure compliance with current GMPs. According to this document, companies outsourcing pharmaceutical operations are responsible for the quality of the final product, not the outsourcing firm.

    Comments on the guidance are due at any time.

    Read more
  • Final Combo Product Guidance Out

    Jan 27, 2017

    In early January, the FDA released its final guidance on cGMPs for combination products. The finalized guidance addresses concerns industry had expressed regarding FDA communications related to combination products. In addition, the guidance discusses the role of the lead center and other Agency divisions responsible for cGMP issues for these types of products.

    Read more
  • President Signs 21st Century Cures Act

    Dec 13, 2016

    On Dec. 13, President Barack Obama signed the 21st Century Cures Act into law. This Act creates a new pathway for regenerative medicines, requires less use of data in bringing drugs and devices to market, and encourages adoption of continuous manufacturing through FDA-provided grants.

    The Act also provides additional funding for research on cancer and opioid addiction.

    Read more
  • FDA Releases Revised Metrics Guidance

    Nov 29, 2016

    On Nov. 23, the U.S. FDA released its revised guidance on quality metrics. This version includes comprehensive definitions for metrics categories as well as reporting tiers for various types of organizations. In addition, the document establishes an initial period where reporting of metrics will be voluntary.

    Comments are due March 27.

    Read more
  • New Pre-RFD Process for Combo Product Submissions

    Oct 3, 2016

    The FDA plans to change its internal procedures for responding to sponsors on preliminary product classification assessments from the Office of Combination Products (OCP). This new process, the Pre-Request for Designation (Pre-RFD) process, will require sponsors to provide a detailed product description. Once OCP receives this information, the Office will make an assessment regarding product classification and Center assignment. The Agency’s goal is to respond to sponsors 60 days following receipt of all the necessary information. A draft guidance on this process is forthcoming.

    Read more
  • Health Canada On Track for Drug Shortage Deadline

    Oct 3, 2016

    This summer, Health Canada announced it is on track to meet requirements for reporting drug shortages via a third-party reporting site by its spring 2017 deadline. After the new reporting site is launched, it will replace the current drug shortages website. Before the new site is up, however, Health Canada expects companies to continue posting information about drug shortages and product discontinuances on the drugshortages.ca website.

    Read more
  • FDA Seeks to Change GLPs

    Oct 3, 2016

    In August, the U.S. FDA proposed amending its Good Laboratory Practice (GLP) regulations to require a complete quality system approach for nonclinical laboratory studies. This approach is called a GLP Quality System and features safety and toxicity studies used to support product submissions to FDA. The Agency also seeks to revise the definition of a “testing facility” in light of current practices, such as multisite studies. This proposed revision is intended to build quality into nonclinical laboratory studies and help ensure data integrity.

    Comments are due Nov. 22.

    Read more
  • FDA Releases Additional Compounding Guidances

    Aug 11, 2016

    On July 7, the U.S. FDA issued two draft guidances regarding compounded drug products that are “essentially a copy” of approved and commercially available drug products. Comments on both draft guidances are due Oct. 11.

    Read more
  • FDA Opens New Oncology CoE

    Aug 11, 2016

    U.S. FDA Commissioner Robert Califf, MD, selected Richard Pazdur, MD, to become acting director of the new Oncology Center of Excellence. This Center will be a place where regulatory scientists and reviewers with oncology clinical expertise in drugs, biologics and devices will collaborate and support an integrated approach to the advancement of cancer treatment.

    Read more
  • FDA/EMA Discussions Include MRI

    Aug 11, 2016

    Over the summer, members of the U.S. FDA met with several European Union regulatory counterparts and stakeholders in Brussels to discuss ways to strengthen their shared commitment to product safety and public health. Discussions covered global supply chain issues, globalization of drug development, and the Mutual Reliance Initiative (MRI). Toward the conclusion of the trip, FDA officials reviewed EMA’s mutual reliance plans. Both agencies expressed hope to continue regulatory alignment.

    Read more
  • FDA Responds to Zika

    Aug 11, 2016

    In a blog post over the summer, the U.S. FDA announced its plans for minimizing the impact of the Zika virus by partnering with other U.S. government agencies, the private sector and the international regulatory community, including the WHO and ANVISA (the Brazilian Health Regulatory Agency) on vaccines and treatments. As of July, 120 FDA staff members are working in response to the outbreak.

    Read more
  • FDA Releases Elemental Impurities Guidance

    Jul 27, 2016

    The U.S. FDA draft guidance, Elemental Impurities in Drug Products, provides recommendations regarding the control of elemental impurities of human drug products marketed in the U.S. in order to remain consistent with the implementation of ICH Q3D. The draft guidance will also assist manufacturers of compendial drug products in responding to the issuance of the USP requirement for the control of elemental impurities.

    Comments on the this guidance are due Aug. 30.

    Read more
  • CDER Launches New Online Export Tracking System

    Jul 7, 2016

    In Q2, CDER launched its new electronic CDER Export Certification and Tracking System. The system allows users to request a CDER Certificate of a Pharmaceutical Product (CPP) online as an alternative to a paper submission. The new software provides many features; including reducing the amount of time it takes to process a certificate, a step-by-step guide to applying for a CPP, real-time validation of data submitted and email notifications regarding the status of a CPP request.

    Read more
  • FDA Remains Committed to EvGen

    Jul 7, 2016

    The U.S. FDA continues to develop EvGen, its national system for evidence generation. In practice, EvGen would be an umbrella for all activities that help inform all stakeholders about making treatment decisions. The platform is built on the concepts of interoperability and connectivity—essential prerequisites for the creation of a successful national system for evidence generation.

    Read more
  • FDA Releases 3D Printing Guidance

    Jul 7, 2016

    The U.S. FDA draft guidance, Technical Considerations for Additive Manufactured Devices, outlines the Agency’s initial thinking on technical considerations specific to medical devices using additive manufacturing (AM), the broad category of manufacturing encompassing 3-dimensional (3D) printing. The draft guidance outlines technical considerations associated with AM processes and recommendations for testing and characterization for devices that include at least one AM fabrication step. This draft guidance is a “leap-frog guidance,” intended to serve as a mechanism by which the Agency can share initial thoughts regarding emerging technologies that are likely to be of public health importance early in product development.

    Comments on this document should be submitted by Aug. 8.

    Read more
  • Sci Tech Council Urges New Tech for Pharma, Biopharma

    Jul 7, 2016

    In April, the Subcommittee for Advanced Manufacturing of the National Science and Technology Council, a Cabinet-level council in the U.S. executive branch, published a report that captured technology areas in advanced manufacturing that are current priorities for the U.S federal government and are strong candidates for focused Federal investment and public-private collaboration. Emerging technology areas include advanced materials manufacturing, engineering biology to advance biomanufacturing, biomanufacturing for regenerative medicine, advanced bioproducts manufacturing and continuous manufacturing of pharmaceuticals.

    Read more
  • FDA Seeks to Strengthen Protection of Reg Filing Data

    Jul 7, 2016
    The U.S. FDA is working on strengthening its protection of pharmaceutical data submitted in regulatory filings during the approval process of new drugs. According to the Agency’s 2015-2018 Information Technology Strategic Plan, the U.S. FDA will implement independent verification and validation for high‐risk systems, move to a next‐generation network security architecture and improve the agency's patch management plan.
    Read more
  • A Case for Quality for Devices

    Jul 7, 2016
    The U.S. FDA’s Case for Quality initiative encourages open engagement between all members of the device ecosystem to enhance the quality of medical devices. This program is one of the Center for Devices and Radiological Health’s 2016-2017 strategic priorities.
    Read more
  • FDA Guidance Looks at ISO Standards for Device App Evaluations

    Jul 7, 2016

    To assist industry in preparing premarket applications, humanitarian device exceptions, investigational device applications and premarket notifications, the U.S. FDA has released its Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process' guidance.

    Comments may be submitted at any time.

    Read more
  • New Quality Metrics Conformance Guide Available

    Jul 7, 2016

    The U.S. FDA recently released its Quality Metrics Technical Conformance Guide, Version 1.0, which serves as the technical reference for the draft FDA guidance, Request for Quality Metrics. The guide provides recommendations about submission of information that will support the FDA’s calculation of quality metrics.

    Read more
  • CBER Releases 2015 Annual Summary

    Jul 7, 2016

    CBER recently published its Annual Summary for 2015. This summary contains an overview of the reports CBER received during the fiscal year, including detailed information regarding the number and types of deviation reports.

    Read more
  • FDA Continues to Look at Compounding

    May 12, 2016

    The U.S. FDA continues to respond to concerns about pharmaceutical compounding with the release of three additional guidances on April 15. These guidances cover prescription requirements, regulation of compounding in state-licensed hospital or health system pharmacies and facility definitions.

    Comments on all three are due by July 18.

    Read more
  • CDER Launches Export Tracking System

    May 12, 2016

    CDER launched its new electronic CDER Export Certification and Tracking System. The system allows users to request a CDER Certificate of a Pharmaceutical Product (CPP) online as an alternative to a paper submission. The new software provides many features; including reducing the amount of time it takes to process a certificate, a step-by-step guide to applying for a CPP, real-time validation of data submitted and email notifications regarding the status of a CPP request.

    Read more
  • FDA Makes Recommendations on Immune Assays for Clinical Trials

    May 12, 2016

    The U.S. FDA has released the draft guidance, Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products. This draft guidance provides recommendations regarding development and validation of immune assays for assessment of the immunogenicity of therapeutic protein products during clinical trials.

    Comments are due June 24.

    Read more
  • FDA Releases 3D Printing Guidance for Device Manufacturers

    May 12, 2016

    The U.S. FDA recently released a draft guidance outlining technical considerations for device manufacturers using 3D printing.

    Comments are due Aug. 8.

    Read more
  • New Prep and Potency Limits for for Biologics Sought

    May 12, 2016

    The U.S. FDA proposes to amend standards for biologics that pertain to preparations and limits to potency due to the availability of new technology and testing capabilities.

    Comments on this proposed rule are due July 18.

    Read more
  • FDA Establishes Combo Product Policy Council

    May 5, 2016

    The U.S. FDA recently established the Agency’s first Combination Products Policy Council. This Council will serve as communications hub for discussing, resolving and implementing product and policy issues related to combination products. In addition, the Council will play an integral role in the development of internal and external communications such as draft guidances, publications and blog posts regarding policy decisions.

    Read more
  • Second U.S. Biosimilar Approved

    May 5, 2016

    On Apr. 5, the U.S. FDA approved a second biosimilar product, Inflectra (infliximab-dyyb), which is administered by intravenous infusion to treat Crohn’s disease, ulcerative colitis and moderate to severe rheumatoid arthritis. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab).

    Read more
  • FDA Releases Data Integrity Guidance

    May 5, 2016

    The U.S. FDA recently released a long-awaited draft guidance on data integrity and compliance with cGMPs. This document clarifies the role of data integrity in cGMPs.

    Comments are due June 14.

    Read more
  • U.S. FDA, Provincial Chinese FDAs Strengthen Cooperation

    May 5, 2016

    Staff from the FDA’s China Office recently met with provincial FDA regulators, industry and academia in China’s Yangtze River Delta region to discuss strengthening partnerships, sharing information and building the foundation for future cooperative engagement.

    Read more
  • FDA to Develop Device Evaluation System

    May 5, 2016

    The U.S. FDA is building the foundations of a national medical device evaluation system to generate better evidence more efficiently for medical device evaluation and regulatory decision making. The collaborative national evaluation system, one of CDHR’s 2016–2017 strategic priorities, will link and synthesize data from different sources across the medical device landscape and improve the quality of real-world evidence that healthcare providers and patients can use to make better informed treatment decisions.

    Read more
  • FDA Approves Change to Continuous Manufacturing

    Apr 14, 2016

    On April 8, for the first time, the U.S. FDA approved a manufacturer’s change from batch to continuous manufacturing. This was for Janssen Product’s HIV-1 medication, Prezista. The company relied on a recently released FDA draft guidance to support the change.

    Read more
  • FDA Looks to Lean Management for Combo Products

    Apr 1, 2016

    In order to improve the overall efficiency, consistency and predictability of combination product review, the U.S. FDA is developing a lean management process mapping approach, which includes an analysis of current processes to highlight existing sources of delay or redundancy, and creation of a “future state” map that identifies a streamlined process that addresses the previously identified delays and redundancies.

    Read more
  • FDA Seeks Human Factors Data

    Mar 10, 2016

    The FDA has issued a draft guidance that lists which devices medical device manufacturers must have human factors data included in their premarket submissions. The Agency believes that inclusion of this data will help it evaluate the potential for use errors in these devices.

    Comments are due May 3.

    Read more
  • CDRH Lists 2016 Guidance Documents

    Mar 10, 2016

    CDRH has released its list of guidance documents for 2016. The documents listed fall under three categories: "A-list" documents the Center fully intends to publish, "B-list" documents to be published as resources permit, and final guidance documents issued in 2006, 1996, 1986 and 1976 subject to retrospective review.

    Read more
  • ORA Ombudsman Takes Office

    Mar 10, 2016

    Jessica Zeller is the new ombudsman in the U.S. FDA’s Office of Regulatory Affairs. Her responsibility is to resolve, when possible, problems between the Agency and external partners.

    Read more
  • CBER Releases 2016 Guidance Doc List

    Feb 29, 2016

    CBER has released the list of guidance documents the Center plans to publish in 2016. Documents of particular interest include early clinical trials with live biotherapeutic products and recommendations for screening donors for Zika in cell, tissue and gene therapy products.

    Read more
  • U.S. Senate Confirms FDA Commissioner

    Feb 25, 2016

    On Feb. 24, the U.S. Senate confirmed Robert Califf, MD, as commissioner of the U.S. FDA. He is currently Vice Chancellor of Clinical and Translational Research at Duke University. His background is in cardiology.

    Califf replaces Margaret Hamburg, who stepped down last year. Stephen Ostroff has been serving as interim commissioner.

    Read more
  • FDA to Delay Some UDI Requirements

    Feb 24, 2016

    On Feb. 3, the U.S. FDA released the draft guidance, Enforcement Policy on National Health Related Item Code and National Drug Code Numbers Assigned to Devices. This guidance will outline FDA’s plan to not enforce the prohibition against providing National Health Related Item Code (NHRIC) or National Drug Code (NDC) numbers on device labels and device packages, with respect to certain finished devices manufactured and labeled prior to Sept. 24, 2018 before Sept. 21, 2021.FDA realizes developers need additional time to ensure that unique device identifiers (UDIs) do not include NHRIC or NDC numbers and does not wish to disrupt the supply chain.

    Comments due April 4.

    Read more
  • FDA Looking at Device Usability

    Feb 15, 2016

    The U.S. FDA recently issued a guidance on applying human factors and usability engineering to medical device due to concerns that user interfaces are designed to minimize or eliminate the risk of errors.

    Read more
  • FDA Continues to Tackle New Tech

    Feb 10, 2016

    The U.S. FDA continues to take steps toward encouraging modernization of pharmaceutical manufacturing, including establishment of the Emerging Technology Team and a recent draft guidance.

    Read more
  • Interconnected Devices Need Special Considerations

    Feb 2, 2016

    Medical devices are becoming ever more interconnected with not just other devices but other forms of technology as well. For this reason, on Jan. 26, the U.S. FDA released the draft guidance, Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices. This document outlines the Agency's "specific considerations related to the ability of electronic medical devices to safely and effectively exchange and use exchanged information," and includes considerations that should be included in the development and design processes for these interconnected devices.

    Comments are due March 28.

    Read more
  • 2016 CDER Guidances Cover Wealth of Issues

    Feb 1, 2016

    CDER has released its list of planned guidances for 2016. These include guidances concerning statistical approaches to support a demonstration of biosimilarity, combination products that utilize software, CMC post-approval change documentation and more.

    Read more
  • Three Main Priorities for Devices in 2016

    Jan 26, 2016

    Recently, the U.S. FDA's Center for Devices and Radiological Health (CDRH) released its 2016-2017 strategic priorities. These priorities fall under one of the three following critical areas: establishing a national evaluation system for medical device, partnering with patients and promoting a culture of quality and organizational excellence.

    Read more
  • FDA Reviewing Cybersecurity for Medical Devices

    Jan 25, 2016

    U.S. FDA recently released a draft guidance regarding cybersecurity of medical devices. A growing number of medical devices, such as "smart" devices,  are networked and incorporate software that could be vulnerable to cybersecurity threats. 

    Comments are due April 21.

    Read more
  • FDA Seeks National Eval System for Devices

    Jan 20, 2016
    Recently, the U.S. FDA's Center for Devices and Radiological Health (CDRH) released its 2016-2017 strategic priorities. These priorities fall under one of the three following critical areas: establishing a a national evaluation system for medical device, partnering with patients and promoting a culture of quality and organizational excellence.
    Read more
  • FDA Approves Record Number of New Drugs

    Jan 12, 2016
    The U.S. FDA approved 45 novel therapies in 2015—placing overall U.S. drug approvals to their highest level since 1996. More than one-third of these were identified as “first-in-class,” meaning drugs utilizing a new and unique form of action to treat a medical condition.
    Read more
  • CDER Plans Ambitious 2016

    Jan 6, 2016

    In late December, the U.S. FDA’s CDER office released its 2016 priorities. These include renegotiating parts of PDUFA and GDUFA, a continuing focus on drug compounding and furthering implementation of Track and Trace.

    CDER Director Janet Woodcock also outlined the Center’s 2015 accomplishments. During the past year, CDER stabilized the new Office of Generic Drugs, completed the standup of the Office of Pharmaceutical Quality, established multiple guidances pertaining to pharmacy compounding and responded to congressional queries related to the 21st Century Cures Act.

    Read more
  • precisionFDA Launched

    Jan 5, 2016
    The U.S. FDA launched its precisionFDA platform in mid-December. This Web- and cloud-based portal allows scientists spanning industry, academia and government to collaborate on the science behind next-generation sequencing (NGS) of DNA. The Agency launched this portal as part of the Precision Medicine Initiative, which began in early 2015 and focuses on fostering the development and expansion of personalized medicines.
    Read more
  • FDA Program Addresses New Tech

    Jan 4, 2016

    On Dec. 23, the U.S. FDA released a draft guidance about a new program for companies interesting in submitting CMC information on emerging manufacturing technologies. This information would be submitted as part of an IND, NDA, ANDA or BLA.

    Comments are due Feb. 22.

    Read more
  • CBER Releases 2015 Highlights

    Dec 22, 2015

    CBER has released its fiscal year report for 2015. Among the highlights:

    • Licensing of the first vaccine in the United States for prevention of meningitis disease caused by Neisseria meningitidis serogroup B
    • Extensive involvement in the containing the Ebola virus outbreak and working with industry groups on strategies for a vaccine
    • More than 70% of CBER's 2015 program alignment objectives were implemented on time

    In addition, CBER Director Karen Midthun, MD, has retired from her position and the FDA is actively seeking a replacement for her role.

    Read more
  • USP Plans Revisions to Water Chapter

    Dec 7, 2015

    USP Chapter <1231> Water for Pharmaceutical Purposes is now under revision. Changes include organizing the chapter into nine specific sections, removal of language redundant to referenced wording in monographs and the addition of a detailed table of contents which will be hyperlinked in future online USP versions.

    Those interested in commenting on the revision can register with the Pharmacopeial Forum for free.

    Read more
  • USP Responds to FDA Biologics Naming Guidance

    Nov 30, 2015

    The United States Pharmacopeial Convention (USP) submitted comments on the U.S. FDA’s Nonproprietary Naming of Biological Products draft guidance, which proposes that all biologic products bear a nonproprietary name designated by the Agency. The USP comments were made in support of a uniform and scientifically based approach to naming that does not create unintended risks for patients and practitioners.

    Read more
  • FDA Provides Update on Cost of Quality for Devices

    Nov 24, 2015

    The U.S. FDA continues to look at Cost of Quality for device manufacturing. The Cost of Quality consists of a focus on quality, stakeholder engagement and data transparency. At this time, the Agency continues to explore development of tools to assess and quantify quality in device manufacturing.

    Read more
  • FDA Releases Finalized Guidance on Formal Meetings with Biosimilar Sponsors

    Nov 24, 2015

    The U.S. FDA recently released its finalized guidance on formal meetings between the Agency and sponsors of biosimilar products that provides recommendations to industry on formal meetings between the Agency and sponsors concerning the development and review of biosimilar products regulated by CDER and CBER.

    This finalizes the April 1, 2013 draft guidance.

    Read more
  • FDA Orange Book Now Available as a Mobile App

    Nov 23, 2015

    The U.S. FDA has released a mobile version of its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly referred to as the "Orange Book") as a PDF document and an app for both Apple and Android products. The app can be purchased through the Apple and Google app stores.

    Read more
  • Guatemalan Medicines Control Lab Retains ISO Accreditation

    Nov 23, 2015

    Guatemala’s official medicines control laboratory has retained its ISO 17025 accreditation, certifying its expanded ability to operate and reliably test the quality of its medicines to world-class standards.

    Read more
  • FDA Releases Revised Compounding Guidance

    Nov 20, 2015

    The revised U.S. FDA Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act Guidance describes some of the possible enforcement actions FDA can bring against individuals or firms that compound drugs in violation of the FD&C Act.

    This document was released in October.

    Read more
  • Rutgers University Receives FDA Grant to Support Continuous Manufacturing in Pharma

    Nov 18, 2015

    The U.S. FDA recently awarded a $4.9 million grant to support research and development of continuous manufacturing techniques for the pharmaceutical industry at the Engineering Research Center for Structured Organic Particulate Systems, a research consortium led by Rutgers University School of Engineering.

    This grant will be administered by NIH over a three-year period and will increase research and development efforts at the Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) over the next 3 years.

    Read more
  • USP Releases Revised Compounding Chapter

    Nov 16, 2015

    In late September, USP released its proposed revision to General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. This revised chapter has been under review since 2010.Changes include collapsing the microbial risk categories of low, medium and high-risk into two categories (Category 1 and 2).

    Comments are due Jan. 31.

    Read more
  • FDA Releases Draft on ICH M4E(R2)

    Oct 16, 2015

    FDA recently released a draft guidance on the ICH revision to its technical requirements for registering pharmaceuticals for human use, also known as M4E(R2). This revision standardizes how benefit-risk information is included in regulatory submissions. FDA hopes the revision facilitates greater communication between regulators and the industry.

    Comments are due Dec. 1.

    Read more
  • FDA Finalizes ICH Q3D Guideline

    Oct 2, 2015

    ICH finalized its Q3D guideline that covers elemental impurities in January. Global regulators identified elemental impurities as an area in need of international harmonization and consensus. This guideline limits metal impurities in drug products and ingredients.

    In September, FDA released its final guidance on ICH Q3D. The guidance establishes permitted daily exposures (PDE) for 24 elements according to toxicity data. In addition, the guidance allows for a risk-based approach to assessing the possibility that elemental impurities with allowed PDE will be present in a drug product.

    Read more
  • FDA Finalizes Rule for Administrative Destruction of Drugs Refused Entry

    Sep 25, 2015

    Effective Oct. 15, FDA now has the authority to destroy any drug valued at $2,500 or less if it has been refused entry into the United States per provisions of the Food and Drug Administration Safety and Innovation Act (FDASIA). This final rule gives the owner of the drug in question the opportunity to receive written notice about the Agency’s intent to destroy the drug and to provide testimony to FDA prior to destruction.

    FDA hopes this serves as a disincentive for importing adulterated, misbranded or unapproved drugs into the country.

    Read more
  • U.S FDA Releases Preliminary Report on Biosimilar Application Workload

    Sep 24, 2015

    On Sept. 24, the U.S. FDA released an interim report that contains preliminary data regarding workload and the full costs associated with reviewing biosimilar applications. According to this data, the labor costs associated with biosimilar reviews at the Agency stood at over $742 million in 2014 compared to $680 million in 2013—a 9% increase.

    Comments are due Oct. 26.

    Read more
  • New FDA Commissioner Nominated

    Sep 16, 2015

    The White House announced on Sept. 15 the nomination of Dr. Robert Califf for the post of Commissioner of the U.S. FDA. Since January, he has been serving as the Deputy Commissioner for Medical Products and Tobacco at the Agency. Prior to joining FDA, he served as Vice Chancellor of Duke University's School of Medicine and was also a professor of cardiology and medicine at the same school.

    He will replace Dr. Margaret Hamburg, who stepped down in March. Dr. Stephen Ostroff has been serving as Acting Commissioner following her departure.

    Read more
  • Naming Conventions for Biologics, Biosimilars Under Consideration

    Sep 1, 2015

    The U.S. FDA has released a guidance regarding naming of biologics and biosimilars. Under the Public Health Service Act, biologics must bear a nonproprietary name with an FDA-designated suffice. The Agency believes that shared nonproprietary names are not appropriate for all biologics. To ensure clear identification of biologics for the purposes of pharmacovigilance and to differentiate biologics that are not interchangeable, the Agency proposes that the suffix for biologics comprises four lowercase letters based on the nonproprietary name of the product.

    As far as interchangeable products, i.e., biosimilars, the Agency is still considering whether the suffix should be unique or share the same suffix as the reference product.

    Comments are due Oct. 27.

    Read more
  • FDA Guidances Now Easier to Search

    Sep 1, 2015

    The U.S. FDA’s new search tool enables those using the FDA website to search the Agency’s growing list of over 3,000 guidance documents quickly and efficiently. This search feature covers the entire FDA space—devices, drugs, biologics, etc. And the information is available in one centralized location for easy searching. Content is also tagged with metadata as well based on identified search terms.

    The search tool can be accessed at www.fda.gov/RegulatoryInformation/Guidances/.

    Read more
  • FDA Updates AMV Guidance

    Aug 20, 2015

    On July 27, the U.S. FDA released an updated version of the Analytical Procedures and Methods Validation for Drugs and Biologics guidance. This guidance replaces the draft guidance of the same name published in Feb. 2014 and explains how to submit analytical procedures and methods validation data to support the documentation of the identity, strength, quality, purity and potency of drug substances and drug products.

    Read more
  • FDA Releases Quality Metrics Guidance

    Aug 20, 2015

    In late July, the U.S. FDA released the draft guidance, Request for Quality Metrics. This document outlines a set of measurements the Agency will use to evaluate the quality of facilities and manufacturing processes. These measurements are: lot acceptance rate, product quality complaint rate, invalidated out-of-specification (OOS) rate and annual product review (APR) or product quality review (PQR) on time rate. Manufacturers will need to submit data to FDA covering the number of attempted lots, lots pending disposition for more than 30 days, lots released, OOS results, etc.

    Comments are due Sept. 25.

    Read more
  • U.S., European Regulators Collaborate on Inspections, Data Integrity

    Jul 20, 2015

    The U.S. FDA, the EMA and the European Commission plan to mutually align with regard to inspections of drug manufacturing sites in addition to stressing the importance of data integrity. Representatives from these three agencies met to discuss cooperative activities for the next two years at a recent meeting at the FDA headquarters in Silver Spring, Md.

    This meeting was part of a regular series of bilateral meetings between senior European and U.S. regulators. Other topics of interest at the meeting covered included cluster reviews for bilateral pharmacovigilance, biosimilars, pediatric and veterinary medicines.

    Read more
  • 21st Century Cures Act Heads to U.S. Senate

    Jul 13, 2015
    On July 10, the U.S. House of Representatives approved the 21st Century Cures Act. The proposed law now heads to the Senate for a vote
    Read more
  • Final Guidance Available on Allowable Excess Volume in Vials

    Jul 2, 2015

    On June 25, U.S. FDA released its final guidance on requirements and regulations pertaining to allowable excess volume in injectable vials. This guidance also reinforces the importance of appropriate fill volumes and labeled vial fill sizes for injectable drug and biological products.

    This guidance replaces the 2014 draft guidance on the topic.

    Read more
  • Proposed Canadian Amendments Address Drug Shortages

    Jul 2, 2015

    Recent proposed amendments to Canada’s Food and Drugs Regulations would require manufacturers to provide notice to Health Canada six months in advance of a possible shortage or discontinuation of a drug product. This legislation follows an increase in shortages of medication within Canada over the past few years. In 2011, Canadian manufacturers created a voluntary, Web-based reporting system (www.drugshortages.ca).

    Comments on the amendments are due Sept. 2.

    Read more
  • Reporting Requirements for CMC Changes

    Jun 2, 2015

    On June 1, the FDA released the draft guidance, Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products. This document outlines the Agency’s current thinking on what CMC information needs to be reported to the FDA in the event it is changed. In addition, the document provides recommendations for managing CMC changes over a product’s lifecycle.

    Comments are due July 31.

    Read more
  • FDA to Withdraw Unfinalized Guidances

    May 11, 2015

    The U.S. FDA recently announced plans to withdraw 47 guidance documents published prior Dec. 31, 2013 that remain unfinalized.

    Read more
  • U.S. FDA Releases Finalized Biosimilars Guidance Documents

    May 4, 2015
    In late April, the U.S. FDA released finalized three guidance documents concerning biosimilars. One document specifies how sponsors should approach developing evidence demonstrating biosimilarity to the reference product. Another addresses quality considerations as well as CMC information used for a biosimilar application. And the third is a Q&A document looking at implementation of the Biologics Price Competition and Innovation Act of 2009.
    Read more
  • 21st Century Cures Draft Legislation Presented

    May 4, 2015
    On April 30, a draft bill of the 21st Century Cures legislation was presented at a hearing in the U.S. House of Representatives. This proposed legislation seeks to streamline the drug approval process. Earlier proposals had sought a more aggressive accelerated approval process for drugs; the current draft document has been scaled-down.

    Read more
  • Former FDA Commissioner Now at Institute of Medicine

    Apr 8, 2015

    Former U.S. FDA Commissioner Margaret Hamburg, MD, is now foreign secretary for the Institute of Medicine, an arm of the National Academy of Sciences. She will advise the Institute on international health matters as well as liaise with foreign medicine and health academies. Her term began April 6 and lasts until June 30, 2019.

    Previously, she served as FDA Commissioner from 2009 to March 2015.

    Read more
  • Proposed Bill to Require Shorter time for FDA to Review Products Approved in Europe

    Mar 24, 2015
    A bill was recently introduced in Congress that, if passed, would require the U.S. FDA to review drug products approved by EU authorities within 90 days. This bill, the Speeding Access to Already Approved Pharmaceuticals Act, seeks to address the lag between approval of a drug product in Europe and in the United States. Currently, the shortest time between approval is six months.
    Read more
  • USP Elemental Impurities Chapters to Align with ICH Q3D

    Mar 11, 2015
    USP announced that the chapters pertaining to elemental impurities, <232> Elemental Impurities—Limits and <2232> Elemental Contaminants in Dietary Supplements, will be applicable Jan. 1, 2018 in order to align <232> with implementation of ICH Q3D.
    Read more
  • FDA Approves First U.S. Biosimilar

    Mar 11, 2015
    The U.S. FDA approved the first U.S. biosimilar, filgrastim-sndz (ZARXIO Injection, Sandoz Inc.). This is a biosimilar for Neupogen, a treatment for lack of white blood cells due to certain cancers.
    Read more
  • Public Docket Established for Compounding Regulations

    Mar 11, 2015
    The U.S. FDA has established a public docket to receive comments on matters concerning pharmacy compounding regulations. This docket is intended for general comments and not directed at a specific document or issue.

    Read more
  • Health Canada Ramps Up Inspections

    Mar 6, 2015

    In late February, Health Canada announced plans to ramp up announced and unannounced inspections of manufacturing facilities due to increasing API concerns and data integrity issues.

    The Agency has also posted an online Inspection Tracker for drug manufacturing facilities that provides a snapshot of the health and safety issues the Agency is tracking on a regular basis.

    Read more
  • U.S. FDA, WHO Recommend New Strains for 2015-2016 Flu Vaccine

    Mar 6, 2015

    Following recommendations from the WHO, the U.S. FDA in early March recommended that the influenza vaccine for the 2015-2016 season include the following strains:  A/California/7/2009, A/Switzerland/9715293/2013, and B/Phuket/3073/2013. This follows a particularly deadly 2014-2015 flu season where the vaccine proved to be only 23% effective.

    Read more
  • U.S. FDA Provides More Info for Compounders

    Feb 25, 2015

    In February, the U.S. FDA released five draft documents concerning drug compounding and repackaging in an effort to ensure relevant entities comply with key public health regulations. These documents follow the enactment of the Drug Quality and Security Act (DQSA) in November 2013. Products compounded in outsourced facilities under certain conditions may be exempt from provision of the Food, Drug, and Cosmetic Act.  

    One document details the regulatory impact of registering as an outsourcer. Another document explains how FDA will respond to repackaging violations by entities falling under the DQSA. A third document describes conditions under which the Agency will not take action for certain regulatory violations that occur due outsourcing facilities mixing, diluting and repackaging biologics. A fourth explains adverse reporting steps for recognized outsourcing facilities. And a fifth, a draft Memorandum of Understanding, outlines a state’s responsibilities when signing the MOU to investigate complaints regarding compounded drug product.

    Comments on all of these documents, except the MOU are due May 20. MOU comments are due June 19.

    Read more
  • FDA Looking at cGMP Recordkeeping

    Feb 25, 2015

    The U.S. FDA released a request for information concerning the recordkeeping of cGMP requirements for finished pharmaceuticals.

    Comments are due March 27.

    Read more
  • FDA Commissioner to Step Down

    Feb 6, 2015
    This week U.S. FDA Commissioner Margaret Hamburg, MD, announced plans to step down from her position at the end of March. Acting Chief Scientist Stephen Ostroff, MD, has agreed to serve as Acting Commissioner when Hamburg leaves.
    Read more
  • Congressional Hearing to Look at Modernizing Flu Vaccine Production

    Feb 3, 2015

    On Feb. 3, the U.S. Congress’ Committee on Energy and Congress will hold a hearing to explore public health responses to seasonal influenza. The hearing will look at modernization of current standards for selecting strains of influenza virus for vaccines as well as improving the production process for flu vaccines.

    Read more
  • Proposed U.S. Legislation Seeks More Efficient FDA Reviews

    Jan 30, 2015
    Recently released draft legislation from the U.S. Congress’ House Energy and Commerce Committee includes provisions focusing on expediting U.S. FDA regulatory review of new and existing drug and device products. This legislation, the 21st Century Cures Initiative, seeks to improve the efficiency of the development process for innovative medical products.
    Read more
  • U.S. FDA Releases Guidance on cGMPs for Combo Products

    Jan 27, 2015

    On Jan. 27, the U.S. FDA released a draft guidance on cGMPs for combination products that further clarifies the final rule on these types of products. The guidance looks at general considerations for cGMP requirements for combination products, addressing the purpose and content of specific cGMP provisions within the final rule. Additionally, the guidance includes hypothetical scenarios clarifying how to comply with specific cGMP requirements.

    Comments are due March 30.
    Read more
  • U.S. FDA, Global Regulators Piloting Device Single Audit Program

    Jan 22, 2015
    Global manufacturers interested in marketing medical devices in Australia, Brazil, Canada and the United States have been invited to participate in the Medical Device Single Audit Program, a pilot program sponsored by the U.S. FDA and regulatory agencies in Australia, Brazil, Canada, and Japan.
    Read more
  • FDA Officially Launches Office of Pharmaceutical Quality

    Jan 14, 2015

    The U.S. FDA officially launched its new Office of Pharmaceutical Quality on January 12. The new office creates a streamlined drug quality program responsible for drug application review, postapproval improvements, and inspections and surveillance of manufacturing facilities.

    Read more
  • FDA Publishes Conclusions of QbD Parallel Assessment with EMA

    Jan 6, 2015

    In late December, the U.S. FDA started publishing joint Q&A documents with EMA outlining conclusions of the agencies’ first parallel assessment of QbD elements of a marketing authorization application. Both FDA and EMA found the assessment useful, reaching agreement on many QbD aspects. Experts from the Japanese Pharmaceuticals Medical Devices Agency also participated as observers for this assessment.

    Read more
  • Electronic Submission Requirements for Standardized Study Data Finalized

    Dec 18, 2014

    On Dec. 18, the U.S. FDA released the final version of the guidance Providing Regulatory Submissions in Electronic Format—Standardized Study Data. This guidance covers how the Agency will implement electronic submission requirements for standardized study data contained in NDAs, BLAs, INDs and ANDAs.

    Comments may be submitted at any time on this document.

    Read more
  • FDA Releases Final Guidance on Electronic Submissions

    Dec 18, 2014

    Along with the final guidance for electronic submissions of standardized study data, on Dec. 18, the U.S. FDA released the final version of the guidance Providing Regulatory Submissions in Electronic Format—Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act, which describes how the Agency will implement electronic submission requirements under the Food and Drug Administration Safety and Innovation Act (FDASIA).

    Comments may be submitted at any time on this document.

    Read more
  • U.S. FDA Releases UDI Roadmap with Brookings

    Dec 10, 2014
    On Dec. 5, the U.S. FDA released a “roadmap,” a report commissioned from the Brookings Institution, for how provider systems, patients, payers, supply chain personnel, and many others, can adopt and utilize unique device identifiers. The Agency hopes these recommendations ensure that the UDI system not only runs efficiently but serves as a tool for unlocking important data to help patients.
    Read more
  • NDA Reviewers to Follow QbR Template

    Nov 20, 2014

    The U.S. FDA has updated its Manual of Policies and Procedures to require reviewers to use a Question-based Review (QbR) for NDAs submitted using a QbR format. In addition, reviewers may choose to follow a QbR review template for NDAs not submitted in a QbR format.

    Previously, QbR had been used solely for ANDAs. This format grew out of the FDA’s Pharmaceutical cGMP’s for the 21st Century Initiative.

    Read more
  • New Guidance Clarifies Adulteration Circumstances

    Oct 27, 2014

    On Oct. 22, the U.S. FDA released a guidance, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection, per Section 707 of the Food and Drug Administration Safety and Innovation Act (FDASIA). This guidance defines the types of actions or inactions that the Agency considers as constituting delaying, denying, or limiting inspection, or refusing to permit an inspection. This draft follows up on the July 2013 draft guidance of the same name; this guidance clarifies FDA expectations regarding the types of circumstances that make a drug adulterated under the Food, Drug and Cosmetics Act.

    PDA commented on the July 2013 guidance.

    Read more
  • Launch Date Announced for Office of Pharmaceutical Quality

    Oct 16, 2014
    The U.S. FDA has announced the launch date of the Office of Pharmaceutical Quality. OPQ is scheduled to launch January 1, 2015 with Janet Woodcock, MD, as the first acting director, supported by Lawrence Yu as Deputy Director.
    Read more
  • Organizational Changes Planned at FDA Office of Regulatory Affairs

    Oct 10, 2014
    The U.S. FDA recently announced changes in the organizational structure of the Office of Regulatory Affairs. To ensure better collaboration with Centers as well as efficiency, each Center will have a single senior executive within ORA responsible for each commodity program. ORA will also work with other Centers such as CBER and CDRH on new initiatives in the area of inspections and training.
    Read more
  • U.S. FDA Releases 2015 Fiscal Year Regulatory Science Priorities for Generics

    Oct 8, 2014
    On Oct. 3, the U.S. FDA published its 2015 regulatory science priorities pertaining to generic drugs in accordance with GDUFA. These priorities were prepared based on comments received at the May 16 public meeting and through public dockets. These priorities include: postmarket evaluation of generic drugs, equivalence of complex products, equivalence of locally acting products, therapeutic equivalence evaluation and standards, and and computational and analytical tools.
    Read more
  • U.S. FDA Plans Further Decisionmaking on Biomarkers

    Oct 7, 2014

    Under the Prescription Drug User Fee Act Reauthorization of 2012, the U.S. FDA is mandated to advance the development of use of biomarkers, which are key in the development of “targeted therapies,” also known as “personalized medicines.” As part of this plan, the Agency partnered with the Brookings Institution’s Engelberg Center for Health Care Reform to host a public workshop Sept. 5 on biomarker development.

    During the workshop, the following were topics of discussion: need for clear standards for the evidence supporting biomarker use, infrastructure and policies promoting development of tests to identify patients for clinical trials, new models for clinical trials that accelerate biomarker development, and methods for assessing treatment effects in small populations.

    The information gathered in this workshop will be used to guide the Agency’s decisionmaking with regard to biomarkers.

    Read more
  • U.S. FDA Compliance Data Available Through Public Dashboard

    Oct 2, 2014

    As part of the Presidential Memorandum on Regulatory Compliance, issued January 2011, the U.S. FDA has released a new online dashboard that allows the public access information on the Agency’s compliance, inspection and recall activities. Providing data from FY 2008 to FY 2013, the dashboard includes information on inspections, warning letters, seizures and injunctions, and statistics specific to recalls. This data will be updated semiannually.

    Hosted in a cloud environment, the data can be downloaded, manipulated through the selection of filters, rearranged to format datasets and columns, drilled down and exported.

    The 2011 Memorandum requires federal agencies to make compliance information publicly available using an easily accessible, downloadable and searchable online format.

    Read more
  • U.S. FDA Finalizes Refuse-to-Receive Guidance on Deficient ANDA Submissions

    Sep 17, 2014

    In early September, the U.S. FDA released a guidance finalizing the October 2013 draft guidance, ANDA Submissions—Refuse-to-Receive Standards. This guidance highlights deficiencies in ANDA submission that could cause the Agency to refuse to receive the submission, meaning the ANDA is not considered sufficiently complete by FDA to permit a more substantive review.

    Comments on the guidance can be submitted at any time.

    Read more
  • U.S. FDA Outlines When it May Refuse an ANDA Due to Lack of Justification of Impurity Limits

    Sep 17, 2014

    On Sept. 17, the U.S. FDA released the draft guidance, ANDA Submissions—Refuse to Receive for Lack of Proper Justification of Impurity Limits. This draft guidance is aimed at applicants submitting abbreviated new drug applications (ANDAs) for approval of drug products with new strengtSh, and highlights specific deficiencies of information that may lead the Agency to refused to receive an ANDA.

    These deficiencies are failing to justify proposed limits for specified identified impurities in drug substances and drug products that are above qualification thresholds, failing to justify proposed limits for specified unidentified impurities that are above identification thresholds, and proposing limits for unspecified impurities (e.g., any unknown impurity) above identification thresholds.

    Comments are due Nov. 17.

    Read more
  • U.S. FDA Guidance on Generics-Related Correspondence Available

    Aug 27, 2014
    In late August, the U.S. FDA announced the release of the draft guidance, Controlled Correspondence Related to Generic Drug Development. This document outlines the process for generic drug manufacturers to submit correspondence when the Agency requests information on generic drug development as well as the FDA’s process for communications related to this correspondence. This part of the Generic Drug User Fee Amendments (GDUFA) of 2012 requiring the Agency to meet certain obligations as part of an effort to speed the delivery of safe and effective generic drugs to the public.

    Comments are due Oct. 27.
    Read more
  • Draft Guidance Looks at GDUFA Performance Metrics for ANDAs

    Jul 21, 2014

    On July 11, the U.S. FDA released a draft guidance that explains how GDUFA performance metrics goals will be applied to ANDAs and prior approval supplements.

    Comments due Sept. 9.

    Read more
  • FDA Draft Guidance Covers ANDA Prior Approval Supplements Under GDUFA

    Jul 21, 2014
    On July 11, the U.S. FDA released a draft guidance intended to assist ANDA applicants preparing to submit Prior Approval Supplements (PASs) and PAS amendments. In addition, the draft describes the Agency’s performance metrics goals for PASs and clarifies how FDA will handle a PAS for an ANDA subject to GDUFA performance metric goals.

    Comments due Sept. 9.
    Read more
  • U.S FDA Provides Update on Medical Device Technology Innovation Partnership

    Jul 17, 2014
    The U.S. FDA provided an update on July 17 regarding the Medical Device Technology Innovation Partnership. This partnership grew out of a CDRH innovation initiative in 2011 to reduce the cost device development and expedite the regulatory evaluation of devices. To help, the Partnership worked with several universities to develop a curriculum to provide students and industry with information about the regulatory framework for developing devices for the market. This curriculum, referred to as the National Medical Device Curriculum consisting of case studies, is now available.
    Read more
  • U.S. FDA Highlights FDASIA Title VII Efforts

    Jul 14, 2014
    Following the two-year anniversary of the signing of the Food and Drug Administration Safety and Innovation Act (FDASIA), the U.S. FDA highlighted its efforts to meet Title VII requirements. Title VII of the law addresses the safety and integrity of drug products and drug product ingredients in the supply chain. The Agency’s efforts to meet Title VII include a proposed and final rule extending its administrative detention authority to include drugs, a draft guidance on actions the FDA considers constitutes delaying, denying or limiting an inspection, a public meeting held July 12, 2013 on Title VII, a draft guidance on the unique facility identifier system, an annual report outlining the number of registered domestic and international establishments, and a proposed rule on administrative destruction of drugs refused importation into the United States.
    Read more
  • U.S. FDA Highlights FDASIA Deliverables on 2-Year Anniversary

    Jul 14, 2014
    The U.S. FDA posted highlights of deliverables required under the Food and Drug Administration Safety and Innovation Act (FDASIA) on its blog following the second anniversary of the law’s passing. These highlights include efforts to address drug shortages, promoting innovation, strengthening user fee programs and enhancing patient engagement.
    Read more
  • U.S. FDA Seeks Comments on Cooperative Manufacturing Arrangements for Biologics

    Jul 7, 2014

    U.S. FDA has announced an opening for public comment concerning a proposed extension of data gathering for cooperative manufacturing arrangements for biologics.

    Comments are due Sept. 5.

    Read more
  • USP <1223> Available for Public Comment

    Jul 7, 2014

    USP’s Expert Microbiology Committee recently published the draft USP 1223, Validation of Alternative Microbiological Methods for comment.

    Comments are due Sept. 30. The draft is available at the Pharmacopeial Forum. This site requires registration but is free to join.

    Read more
  • U.S. FDA 4-Year Strategic Plan Addresses IT

    Jul 7, 2014

    The U.S. FDA released its strategic plan for 2014-2018 on July 1. Highlights include expanding data sharing and bioinformatics capabilities along with overall increased investment in IT.

    Comments are due July 31.

    Read more
  • FDA Releases Interim Guidance on cGMPs for Compounding Facilities

    Jul 2, 2014
    The Agency is seeking input from stakeholders on an interim guidance concerning cGMPs for facilities registering with FDA as compounding outsourcing facilities under the Drug Quality and Security Act. Specifically, FDA intends to focus on how such facilities can meet 21 CFR Parts 210 and 211. In addition, the Agency seeks comments on alternative approaches that would enable an outsourcing facility to have confidence in the quality of incoming components from sources used by multiple outsourcing facilities without each individual outsourcing facility having to conduct periodic laboratory testing to confirm the information in the third-party supplier's certificate of analysis, and alternative approaches minimizing the need for outsourcing facilities to establish an in-house laboratory while providing confidence about the accuracy of testing performed by a third party used by more than one outsourcing facility.

    Comments are due Oct. 31.
    Read more
  • U.S. FDA Guidance on 503A Enforcement of Compounders

    Jul 2, 2014
    There is a U.S. FDA guidance available announcing the Agency’s plans to enforce provisions of the Food, Drug, and Cosmetic (FD&C) Act for regulation of compounding facilities. The Act was recently amended by the Drug Quality and Security Act. Specifically, the guidance addresses provision 503A which covers compounded drug products.
    Read more
  • U.S. FDA Seeks to Reduce Drug Shortage Impact

    Jun 30, 2014
    The U.S. FDA remains committed to reducing the impact of shortages of critical drugs, including encouraging more suppliers, expediting review of new drug applications for products in short supply, and greater communication on impending shortages.
    Read more
  • U.S. FDA GUDID Guidance Available

    Jun 30, 2014
    U.S. FDA guidance on Global Unique Device Identification (GUDID) finalizes all section of the document, Global Unique Device Identification (GUDID): Draft Guidance for Industry, including sections on how device labelers interface with the GUDID, establishment of GUDID accounts and initial submissions.
    Read more
  • U.S. FDA Guidances Offer Social Media Recommendations

    Jun 18, 2014

    On June 17, the U.S. FDA released two draft guidances concerning social media communications from companies concerning their drug and medical device products. The first guidance offers the Agency’s recommendations for communicating risk and benefit information for products using character space-limited online platforms such as Twitter. The second guidance offers recommendations for how companies can respond to and correct online third parties communicating inaccurate or misleading information about a product.

    Comments for both guidances are due September 16.

    Read more
  • U.S. FDA Guidance Covers Improving ANDA Submissions

    Jun 12, 2014
    Comments due Aug. 11 on the U.S. FDA draft guidance, ANDA Submissions—Content and Format of Abbreviated New Drug Applications. As part of an effort to increase the number of original ANDAs the Agency can receive while also shortening the review cycles, the FDA seeks to improve the quality of original ANDA.
    Read more
  • FDA Issues First Phase of Global Unique Device Identification Database Guidance

    Jun 11, 2014
    To quickly provide industry with information critical to successful use of the Global Unique Device Identification Database (GUDID), the U.S. FDA is issuing the GUDID Guidance in two phases.The first phase includes updates to sections on establishing and using a GUDID account, the unique device identifier, Global Medical Device Nomenclature (GMDN), and electronic records/electronic signatures. Also included in this phase are GUDID attributes mapped to a fictitious medical device label and a glossary.

    To access an overview of the GUDID database, visit http://www.fda.gov/medicaldevices/deviceregulationandguidance/uniquedeviceidentification/globaludidatabasegudid/default.htm.
    Read more
  • Secure Supply Chain Pilot Program Open

    Mar 12, 2014

    In late February, the U.S. FDA officially initiated its two-year Secure Supply Chain Pilot Program. The Agency selected 13 companies to participate in this program; these  companies will be allowed to receive expedited entry for importation of up to five selected drug products into the United States. The Agency will use this program to evaluate resource savings efforts that focus less on low-risk drugs coming into the country, and instead emphasize surveillance on importations of high-risk drug products.

    Read more
  • Legislation Targeting Compounders in Senate

    Nov 13, 2013

    In early October, the U.S. Congress released a proposed bill, the Drug Quality and Security Act, which includes language tightening U.S. FDA oversight of compounding pharmacies. The bill creates a class of compounders, called “outsourcing facilities,” that would be regulated by the Agency. This classification will be voluntary; if enacted, hospitals and clinics would have the option of choosing to use either the FDA-regulated pharmacy or one that is not.

    The bill also creates a “track and trace” system for following the movement of prescription drugs across the supply chain. This system would require bar codes on packages of drugs shipped.

    Read more
  • Comments Due on Postapproval Modifications to Combination Products Draft Guidance

    Sep 11, 2013

    In January, the U.S. FDA released a draft guidance, Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA, intended to provide underlying elements for determining which marketing submission should be required for postapproval changes to a combination product approved under one marketing application, such as a biologics license application (BLA), a new drug application (NDA) or a device premarket approval application (PMA). Comments are due by April 22.

    Comments should be submitted by April 22.

    Read more
  • U.S. FDA Adopts ICH ANDA Guidelines

    Jun 10, 2013

    The U.S. FDA has adopted International Conference on Harmonization (ICH) guidelines concerning requirements for ANDA stability testing. The ICH guidelines adopted cover stability testing of new drug substances, photostability testing new drug substances, stability testing for new dosage forms, bracketing and matrixing designs for stability testing of new drug substances, and evaluation of drug safety data.

    Read more
  • Form 3486 Addendum Now Available

    Jun 5, 2013

    In June, the U.S. FDA announced the Agency had developed a Web-based addendum to Form 3486 that provides additional information when a BPD report has been reviewed and evaluated by the Agency as a possible recall. The additional information requested includes information that is not contained in Form 3486, such as distribution patterns, methods of consignee notification, consignees of products for further manufacturing, additional product information, updated product dispositions and industry recall contacts.

    Comments are due Aug. 12.

    Read more
  • U.S. FDA Releases ICH Q4B Guidance

    May 28, 2013

    Comments can be submitted at any time for the recent guidance released by the U.S. FDA on Q4B evaluation and ICH harmonization. The Agency worked with ICH on the development of this guidance which contains results of ICH’s Q4B evaluation of bulk density text from U.S., European and Japanese pharmacopoeias. This guidance recognizes interchangeability between these local pharmacopoeias in an effort to avoid redundant testing.

    Read more
  • USP Launches Anti-Counterfeiting Initiative

    May 13, 2013

    The United States Pharmacopeia announced the launch of its Center for Pharmaceutical Advancement and Training (CePAT) in May. CePAT is located in Accra, Ghana and will play a key role in tackling the issue of drug counterfeiting in sub-Saharan Africa. Counterfeit medications are a significant issue in this region, as shown by 90% of drug samples tested by USP in Sub- Saharan Africa failed API or sterility.

    This new center is also part of a larger effort within USP promoting access to good quality medications across the globe.

    Read more
  • Guidance on Beta-Lactam Drugs Now Available

    Apr 17, 2013

    On April 17, the U.S. FDA released a guidance concerning implementation of controls for prevention of cross-contamination of pharmaceuticals and APIs with non-penicillin beta-lactams. At this time, CGMPs only require separation measures for penicillin products. Due to potential cross-contamination health risks, FDA would like to expand the framework to include separation measures for all classes of beta-lactam drugs.

    Comments can be submitted at any time for this proposed guidance.

    Read more
  • New Pilot Program for INDs

    Apr 8, 2013

    The CBER division of the U.S. FDA is inviting IND sponsors to participate in the Center’s eSubmitter Program, which is an automated, computer-based program, as part of a pilot of the system. eSubmitter includes a template geared specifically for IND applications pertaining to antivenom drugs. This pilot is supposed to provide industry and regulatory staff an opportunity to review the new system and ascertain if it facilitates IND submissions.

    Companies interested in participating must submit a request by July 8; only nine sponsors will be selected for the pilot program.

    Read more
  • U.S. FDA Posts Glass Syringe Guidance

    Apr 3, 2013

    The U.S. FDA’s Office of Combination Products released its draft guidance, Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4, April 3. This draft guidance offers information for sponsors seeking to conform to ISO Standard 11040-4 for glass syringe product submissions. The Agency has stated that demonstrating ISO conformity does not necessarily ensure that the glass syringe can be joined properly to connecting devices. This guidance identifies additional information that needs to be included in exemptions and applications. Companies involved in developing or marketing injection devices or components are urged to become familiar with the guidance. Comments are due July 2.

    Read more
  • New Scale-Up and Post-Approval Changes Guidance Available

    Apr 1, 2013

    In early April, the U.S. FDA released a draft guidance for industry concerning scale-up and post-approval changes, titled, SUPAC: Manufacturing Equipment Addendum. The Agency has revised the draft manufacturing equipment addenda by removing equipment examples and clarifying referenced processes. This draft supersedes addenda released in 1998 and 1999.

    Comments on the draft guidance are due by July 1.

    Read more
  • Comment on U.S. FDA's Draft Plan for Benefit-Risk Assessments

    Mar 8, 2013

    A draft five-year plan is now available showing the U.S. FDA's approach to implementing a framework for benefit-risk assessment in the drug review process under PDUFA.

    Comments should be submitted by May 7.

    Read more
  • Comment on Financial Disclosure Requirements for Clinical Investigators

    Feb 26, 2013

    Submit your comments at any time on the U.S. FDA's recent guidance concerning financial disclosures for clinical investigators.This guidance will help clinical investigators, industry, and U.S. FDA staff in interpreting and complying with regulations on financial disclosure information required by clinical investigators, including the Agency’s FAQs regarding financial disclosure by clinical investigators. Ultimately, this guidance finalizes the draft guidance on the same topic dated May 2011 and replaces the guidance entitled, Guidance for Industry: Financial Disclosure by Clinical Investigators, dated March 2001.

    Read more
  • Comment on Premarket Reviews Draft Guidance

    Feb 15, 2013

    A U.S. FDA draft guidance concerning the establishment of criteria for individuals performing premarket reviews of medical devices is now available.

    Comments should be submitted by April 16.

    Read more
  • U.S. FDA Seeks Comments on Drug Shortages Strategic Plan

    Feb 12, 2013

    Under the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), the U.S. FDA is required to draft a strategic plan to tackle the issue of drug shortages. The Agency's Drug Shortages Task Force, therefore, seeks public comments on the development of the strategic plan. The strategic plan will focus on both drug and biological product shortages.

    Comments should be submitted by March 14.

    Read more
  • U.S. FDA Releases Therapeutic Protein Products Draft Guidance

    Feb 11, 2013

    On February 11, the U.S. FDA released a draft guidance for industry addressing immunogenicity assessments for therapeutic protein products. This guidance is intended to assist drug manufacturers in developing risk-based approaches in both the preclinical and clinical phases of the development of therapeutic protein products that evaluate and mitigate immune responses that could adversely affect safety and efficacy.

    Adverse events caused by immune responses have caused sponsors to terminate development of therapeutic protein products. The Agency hopes the guidance will spur the development of risk mitigation strategies.

    Comments should be submitted by April 12.

    Read more
  • U.S. FDA Seeks NME and BLA Information Collection

    Feb 9, 2013

    The U.S. FDA proposes to collect information from interviews with manufacturers submitting new molecular entity new drug applications (NMEs) and original biologics license applications (BLAs). This proposal is part of the Agency's performance commitments under PDUFA.

    Comments should be submitted by April 22.

    Read more
  • U.S. FDA Photosafety Testing Guidance Available

    Feb 4, 2013

    The U.S. FDA has published a draft guidance on photosafety testing with the goal of harmonizing international assessments. In November 2012, the ICH Steering Committee released a draft guidance, S10 Photosafety Evaluation of Pharmaceuticals, for public comment. This guidance provides recommendations on when photosafety testing is needed in the evaluation of pharmaceuticals. The FDA guidance seeks to harmonize U.S. thinking on photosafety with the ICH guidance.

    Comments should be submitted by March 21.

    Read more
  • U.S. FDA Guidance on MDUFMA Fee Waivers

    Jan 31, 2013

    A U.S. FDA guidance is available concerning criteria for small businesses to receive Medical Device User Fee and Modernization Act (MDUFMA) fee waivers. In an effort to avoid harming small businesses, MDUFMA provides for reduced or waived fees for applicants who qualify as a "small business." There are two levels of fees: a standard fee and a reduced small business fee. A business qualifies for a small business if reported gross receipts or sales are of no more than $100 million on the company's federal income tax return for the most recent tax year.

    Comments should be submitted by March 4.

    Read more
  • Final Rule Available on CGMPs for Combination Products

    Jan 22, 2013

    The U.S. FDA published the Agency's final rule on CGMP requirements for combination products in January. This rule is supposed to clarify which CGMP requirements apply for drugs, devices and biological products united to create combination products. It also lays out a streamlined regulatory framework for companies to demonstrate CGMP compliance for "single-entity" and "copackaged" combination products.

    The Agency began addressing CGMP requirements for combination products in 2004 with a draft guidance before issuing a proposed rule in 2009. This final rule will be effective July 22.

    Read more
  • Draft Guidance Available on Submissions Using eCTD Specifications

    Jan 3, 2013

    The U.S. FDA has posted a draft guidance concerning regulatory guidelines for the electronic submissions of applications for drug products, including NDAs, ANDAs, BLAs, and INDs. The guidance outlines requirements for electronic submissions in an FDA-approved format. At this time, the Agency can process and review submissions using eCTD specifications.

    Comments on the draft guidance are due March 4.

    Read more
  • Premarket Approval Applications Acceptance and Filing Reviews Guidance Posted

    Jan 2, 2013

    Superseding the U.S. FDA's May 2003 guidance on premarket approval filing, there is a new guidance available on the acceptance and filing review criteria for premarket approval applications (PMAs). Due to recent changes in the law, including the reauthorized Medical 88 Device User Fee Amendments of 2012 (MDUFA III), acceptance review has taken on a larger role in encouraging quality PMA applications and allowing FDA to allocate resources more adequately on completed applications. The new guidance includes a modified PMA filing checklist.

    Read more